Clozapine is an atypical neuroleptic with efficacy superior to that of conventional antipsychotic agents (Kane et al. 1988; Leiberman et al. 1989; Breier et al. 1994a; Breier et al. 1994b; Meltzer 1995; Meltzer et al. 1996) . A relatively consistent clinical effect of clozapine is a robust increase in norepinephrine (NE) levels, both in cerebrospinal fluid (CSF) (Ackenheil 1989; Leiberman et al. 1989; Leiberman et al. 1991; Pickar et al. 1992 ) and in plasma (Pickar et al. 1992; Green et al. 1993; Davidson et al. 1993; Breier et al. 1994b; Breier 1994; Brown et al. 1997 ). Plasma NE increases have been related to clinical improvement (Breier et al. 1994b; Breier 1994) , suggesting that this neurochemical effect may be involved in clozapine's therapeutic mechanism of action. In contrast, traditional antipsychotic agents studied to date have no or negligible influence on NE levels (Pickar et al. 1992; Breier et al. 1994b; Brown et al. 1997) .
Clozapine is an atypical neuroleptic with efficacy superior to that of conventional antipsychotic agents (Kane et al. 1988; Leiberman et al. 1989; Breier et al. 1994a; Breier et al. 1994b; Meltzer 1995; Meltzer et al. 1996) . A relatively consistent clinical effect of clozapine is a robust increase in norepinephrine (NE) levels, both in cerebrospinal fluid (CSF) (Ackenheil 1989; Leiberman et al. 1989; Leiberman et al. 1991; Pickar et al. 1992 ) and in plasma (Pickar et al. 1992; Green et al. 1993; Davidson et al. 1993; Breier et al. 1994b; Breier 1994; Brown et al. 1997 ). Plasma NE increases have been related to clinical improvement (Breier et al. 1994b; Breier 1994) , suggesting that this neurochemical effect may be involved in clozapine's therapeutic mechanism of action. In contrast, traditional antipsychotic agents studied to date have no or negligible influence on NE levels (Pickar et al. 1992; Breier et al. 1994b; Brown et al. 1997) .
The mechanism of clozapine-induced NE elevation has not been established. Plasma levels of any endogenous biochemical represent the ratio of the rate of release of the substance into the bloodstream (spillover) and clearance of the substance from the bloodstream. Clozapine-induced elevations in plasma NE levels, therefore, could result from increased spillover, deceased clearance, or a combination of both.
Neuronal uptake by sympathetic nerves constitutes a determinant of plasma NE spillover (Eisenhofer et al. 1996) and clearance (Esler et al. 1981; Eisenhofer et al. 1991) . After neuronal uptake of NE, some of the NE in the axoplasm undergoes oxidative deamination by mitochondrial monoamine oxidase (MAO), forming dihy-droxyphenylglycol (DHPG). Inhibition of neuronal uptake, therefore, could explain the finding of normal plasma DHPG levels, despite high plasma NE levels, in clozapine-treated patients (Breier et al. 1994b; Breier 1994) .
The present study applied a comprehensive neurochemical approach to examine the mechanisms responsible for clozapine-induced elevations in plasma NE concentrations. This approach was based on intravenous infusion of tracer amounts of H-DHPG responses provided the basis for assessing both of these processes. Plasma levels of the NE precursor dihydroxyphenylalanine (DOPA) and of the dopamine metabolite DOPAC were also examined to provide information about NE synthesis and further information about intraneuronal metabolism by MAO.
METHODS

Subjects
Ten clozapine-, 7 fluphenazine-, and 7 placebo-treated patients meeting DSM-IV criteria for schizophrenia, as determined by structured diagnostic interview, underwent this study at the National Institutes of Health Clinical Center. All subjects gave written informed consent to participate in the protocol, which was approved by the National Institute of Mental Health Review Board. All subjects were in good physical health, as evidenced by physical examination, ECG, and screening blood tests. The treatment groups did not differ in demographic or clinical characteristics (Table 1) .
The patients were on a stable dose of medication or medications free for a minimum of 2 weeks. Doses were varied to achieve maximal clinical efficacy (clozapine mean dose Ϯ SD: 385.00 Ϯ 178.4 mg per day; fluphenazine mean dose Ϯ SD: 21.02 Ϯ 3.95 mg per day).
Procedure
The subjects were studied after having fasted and refrained from alcohol, tobacco, caffeine, or physical activity for at least 10 hours. With the patient supine, an arterial catheter was inserted percutaneously in a radial artery after local anesthesia of the overlying skin. An antecubital intravenous catheter was inserted into the contralateral arm. After 60 min, 3 H-NE ([1,7-3 H]NE, 14-22 Ci/mmol; New England Nuclear, Boston, MA) in 50 cc normal saline was infused intravenously at 0.75 ml/ min. Arterial blood samples (7-8 ml) were obtained at 15, 30, 45, and 60 min after the 3 H-NE infusion began.
Biochemical Variables
Blood for assays was collected in heparinized tubes and placed on wet ice. After separation by refrigerated centrifugation, the plasma was stored at Ϫ 80 Њ C. Plasma catechol levels were assayed using liquid chromatography with electrochemical detection (Eisenhofer et al. 1986 (Esler et al. 1979) . Neuronal uptake (Eisenhofer et al. 1991) and NE stores (Eisenhofer et al. 1991; Eisenhofer et al. 1996) were assessed from the 
Statistical Analyses
The data were analyzed using Statistica (StatSoft, Inc., Tulsa OK 74104). Results across the 4 sampling points were averaged and expressed as means Ϯ standard deviation (SD). Differences among the treatment groups were assessed by one-way repeated-measures analysis of variance (ANOVAs), with drug condition (clozapine, fluphenazine, placebo) as the grouping factor. When a group effect was significant, post hoc Newman-Keuls t -tests were performed. Time-related trends in 3 H-DHPG/ 3 H-NE ratios were examined by two-way ANOVAs, with drug condition as the grouping factor and time as the within-subjects factor. A p value less than .05 defined statistical significance. All tests were two-tailed.
RESULTS
Catechol Levels
Clozapine-treated patients had more than three times higher arterial plasma NE levels (F ϭ 9.39; df ϭ 2; p ϭ .001, Figure 1 ) than patients treated with fluphenazine or placebo. Post hoc analyses revealed significantly higher NE levels in subjects treated with clozapine than with fluphenazine ( p ϭ .002) or placebo ( p ϭ .005). There were no significant NE differences between fluphenazine and placebo treatment groups. The groups did not differ in plasma levels of DOPA or DOPAC (Table 2) .
NE Spillover
NE spillover was increased by more than threefold in clozapine-treated patients (F ϭ 9.41; df ϭ 2; p ϭ .001) (Figure 1 ), as compared with both of the other groups (fluphenazine, p ϭ .004; placebo, p ϭ .002). Fluphenazine did not alter NE spillover.
NE Clearance
The three treatment groups did not differ in plasma NE clearance (F ϭ 0.42; df ϭ 2; p ϭ .66) (Figure 1 ). H-NE ratios increased progressively with time (F ϭ 18.53; df ϭ 3; p Ͻ .0001). The increases did not differ among the groups, as indicated by a statistically nonsignificant interaction effect for group with time (F ϭ 0.91; df ϭ 6,3; p ϭ .49, Figure 2 ).
Time-Related Trends in
DISCUSSION
The major finding of this study is that high plasma NE levels in clozapine-treated patients result entirely from increased NE spillover and not from decreased clearance. Several factors determine NE spillover, other than exocytotic release in response to sympathetic nerve traffic. Probably the most important is reuptake. Estimates of the efficiency of reuptake of endogenously released NE range up to about 90% (Iversen 1973; Esler et al. 1990 ). Clearly, even a small amount of inhibition of re- Figure 1 . NE plasma level, NE spillover, and NE clearance in schizophrenic patients treated with clozapine (n ϭ 10), fluphenazine (n ϭ 7), and placebo (n ϭ 7). uptake would augment the amount of NE entering the plasma for a given rate of exocytotic release from the terminals. The finding of high plasma NE levels without a corresponding increase in plasma DHPG would support this sort of mechanism, because plasma DHPG reflects the metabolism of axoplasmic NE (Goldstein et al. 1988; . All other things being the same, decreased reuptake of NE would increase NE spillover but decrease plasma DHPG levels. Because we previously observed this pattern in clozapine-treated patients (Breier et al. 1994b ), the present study focused especially on the issue of possible neuronal uptake blockade by clozapine.
Neuronal reuptake contributes to clearance of circulating NE in humans (Esler et al. 1981; Eisenhofer et al. 1991) . The present finding of no change in NE clearance in clozapine-treated patients argues against inhibition of neuronal uptake as a basis for high plasma NE levels in these patients. To examine neuronal uptake more specifically, we measured the arterial plasma H-DHPG, and DOPAC in clozapine-treated subjects renders MAO inhibition a highly unlikely mechanism of action of clozapine. Moreover, blockade of the vesicular monoamine transporter accelerates the rate of attain- 
Figure 2. [ 3 H]DHPG/[
3 H]-NE ratio in schizophrenic patients treated with clozapine (n ϭ 10), fluphenazine (n ϭ 7), and placebo (n ϭ 7).
H-NE infusion (Eisenhofer et al. 1991; Eisenhofer et al. 1996) . In the present study, however, clozapine treatment did not affect the rate of increase in arterial plasma 3 H-DHPG concentrations. A decreased storage pool of NE, therefore, does not explain the discrepancy between plasma NE and DHPG responses to clozapine.
If a chronic increase in the rate of sympathetic nerve traffic increased the relative proportion of vesicles fused with the membrane surface, then we might expect a relative increase in DHPG formation from reuptake of released NE and a relative decrease in DHPG formation from net leakage from the vesicles into the axoplasm. Thus, over-all DHPG production might remain unchanged. Patients with disorders presumably associated with chronically compensatory increased sympathetic nerve traffic, such as dihydropteridine reductase deficiency , Menkes disease (Kaler et al. 1993) , familial dysautonomia (Axelrod et al. 1996) , and partial deficiency of L-aromatic-amino-acid decarboxylase (unpublished observations), do have high plasma NEϺDHPG ratios, consistent with a shift in the vesicles toward the membrane surface, where loss of NE via leakage and metabolism would be offset by loss of NE via exocytosis. Therefore, a mechanism of clozapine's action may involve fusion of NE storage vesicles with the axonal membrane.
In conclusion, clozapine elevates arterial plasma NE levels via increases in NE spillover; whereas, NE reuptake, synthesis, or metabolism are not affected by this drug.
